HO
Werewolf Therapeutics, Inc.
HOWL · NASDAQ
$0.97 +2.80% (+$0.03)
1M +143.34%
Market Cap $45.9M
P/E Ratio -
Div. Yield -
ROE 166.99%
Bulios Fair Price
$1.14
18.0% upside
Current Price
$0.97
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HOWL is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
71 /100
Cheap P/B 2.82x
P/S 2.18x
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 41.25%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 164.82%
Op. margin 121.78%
FCF margin 143.56%
Quality
11 /100
Poor ROE 166.99%
ROA 143.30%
Asset turnover 0.87x
Debt
69 /100
Low Current ratio 2.91x
Int. coverage -5.64x
Debt/Equity 0.00x
Stability
17 /100
Unstable Rev. volatility 67.64%
EPS volatility 51.34%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HOWL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Daniel J. Hicklin
Employees
39
Headquarters
Watertown
Upcoming events
03 NOV
Earnings
Upcoming earnings report